Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18080459 | 0.86 | TRPV1 (0.34) | TRPV1EIF4A3CYP1A2CYP2C19TNKS | |
| SCHEMBL18080471 | 0.86 | TRPV1 (0.37) | TRPV1EIF4A3KDM5BCYP1A2CYP2C19 | |
| SCHEMBL18080479 | 0.82 | PDE2A (0.33) | TRPV1EIF4A3CYP1A2CYP2C19 | |
| SCHEMBL18080497 | 0.81 | RPS6KA3 (0.31) | TRPV1EIF4A3RPS6KA3 | |
| SCHEMBL18081931 | 0.79 | TNKS2 (0.34) | TNKSPARP1TNKS2PARP2PARP3 | |
| SCHEMBL18080455 | 0.78 | CYP1A2 (0.38) | TRPV1EIF4A3KDM5BCYP1A2CYP2C19 | |
| SCHEMBL18080467 | 0.76 | SMPD3 (0.33) | TRPV1 | |
| SCHEMBL16631411 | 0.76 | TNKS (0.36) | CYP1A2TNKSPARP1TNKS2PARP2 | |
| SCHEMBL18080452 | 0.75 | KDM5B (0.32) | KDM5BCYP1A2CYP2C19 | |
| SCHEMBL18080463 | 0.75 | EIF4A3 (0.33) | TRPV1EIF4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | TRPV1 3709/4885EIF4A3 1031/4885KDM5B 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.